Vaccine最新文献

{"title":"Evaluating concurrency and gaps between self-report and vaccine card data for COVID-19 vaccination","authors":"Marie C.D. Stoner ,&nbsp;Jenna Michaels ,&nbsp;Jacob B. Stocks ,&nbsp;Noah Mancuso ,&nbsp;Zachary Soberano ,&nbsp;Erica Browne ,&nbsp;C. Lily Bond ,&nbsp;Ibrahim Yigit ,&nbsp;Allysha C. Maragh-Bass ,&nbsp;Audrey E. Pettifor ,&nbsp;Kathryn E. Muessig ,&nbsp;Maria Leonora G. Comello ,&nbsp;Margo Adams Larsen ,&nbsp;Lisa B. Hightow-Weidman ,&nbsp;Henna Budhwani","doi":"10.1016/j.vaccine.2025.127136","DOIUrl":"10.1016/j.vaccine.2025.127136","url":null,"abstract":"<div><div>We compared self-reported vaccination to vaccine card data to assess concurrency in a sample of Black young adults in Georgia, Alabama, and North Carolina. We described vaccine card versus self-reported data over time and examined discrepancies in reporting between these two sources. Results indicated strong currency suggesting collection of self-reported data may be an acceptable proxy to requiring official vaccine documentation. However, since 58 % of participants did not upload a vaccine card, finding should be applied with caution. Minor differences were found and were generally due to boosters that were self-reported but were not on cards. The discrepancy in number of vaccines and boosters was likely because COVID-19 vaccination has become routine and vaccine cards are not being updated regularly. At this stage in the pandemic and for other vaccinations that become routine and are administered at pharmacies, self-report may be a reliable indication of the number of vaccinations received.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127136"},"PeriodicalIF":4.5,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of recombinant Lactobacillus vector-based expressing IFITM3 protein anti-PRV infection in mice.","authors":"Fan Zheng ,&nbsp;Maokun Zhu ,&nbsp;Hengdong Ran ,&nbsp;Jiayi He ,&nbsp;Binghan Bai ,&nbsp;Simeng Feng ,&nbsp;Wei Dong ,&nbsp;Bin Li ,&nbsp;Lixin Wen ,&nbsp;Xiaomin Yuan","doi":"10.1016/j.vaccine.2025.127093","DOIUrl":"10.1016/j.vaccine.2025.127093","url":null,"abstract":"<div><div>Pseudorabies virus (PRV) causes high mortality encephalitis in newborn piglets, abortion and stillbirth in sows, resulting in huge economic losses to the swine industry. Interferon-induced transmembrane proteins (IFITMs) play a crucial role in the innate immune response triggered by viral infection. Lactic acid bacteria (LABs) are good candidates for the development of new oral vaccines and are attractive alternatives to attenuated pathogens. “Here we tested the capacity of a LAB vector expressing the IFITM3 protein (r-LAB-I3), delivered by oral gavage, to protect mice against PRV challenge. Furthermore, the r-LAB-I3 treated groups showed markedly diminished levels of viral DNA in brain, lung, spleen and liver tissues, which resulted in protection against brain and lung damage. Moreover, the inhibitory effect of IFITM3 on PRV circumvents the upregulation of inflammatory cytokines. As r-LAB-I3 oral gavage platforms can restrict in various organs and tissues of PRV in mice, recombinant LAB may generate additional innovative and efficient live vector anti-PRV candidates.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127093"},"PeriodicalIF":4.5,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of health systems in shaping vaccine decisions: Insights from Italy, Mexico, the United Kingdom, and the United States","authors":"Catherine Arsenault ,&nbsp;Sindhu Ravishankar ,&nbsp;Todd Lewis ,&nbsp;Patricio Armeni ,&nbsp;Kevin Croke ,&nbsp;Svetlana V. Doubova ,&nbsp;Martin McKee ,&nbsp;Rosanna Tarricone ,&nbsp;Margaret E. Kruk","doi":"10.1016/j.vaccine.2025.127134","DOIUrl":"10.1016/j.vaccine.2025.127134","url":null,"abstract":"<div><h3>Background</h3><div>The demographic drivers of vaccine uptake and confidence have been well-documented in diverse contexts. However, the role of health systems in improving vaccine uptake and confidence has been less discussed particularly in the post-pandemic period.</div></div><div><h3>Methods</h3><div>Using nationally representative surveys of adults conducted between December 2022 and April 2023 in Italy, Mexico, the United Kingdom (UK), and the United States (US), we examined demographic, health, and health system determinants of vaccine confidence and uptake of four vaccines for adult respondents or their children: COVID-19, influenza, human papillomavirus (HPV), and measles, mumps, and rubella (MMR). Logistic and linear regression models explored associations between predictors of interest and vaccine outcomes, with coefficients reported on the risk difference and risk ratio scales.</div></div><div><h3>Findings</h3><div>A total of 5180 respondents were surveyed, one-third of whom had at least one child aged 1–18 years. Having received at least three other preventive health services in the last year was associated with COVID-19 and Flu vaccination in all countries (Risk ratio (RR) 1.04–1.54) and with vaccine confidence in the US (RR 1.10). Having at least three health care visits in the last year and having a regular health provider were also associated with a higher likelihood of vaccine uptake and confidence in some countries. Being confident in one's ability to obtain and afford quality care (i.e. “health security”) had a positive association with at least one outcome in all countries except Mexico (RR 1.07–1.36) and with children COVID vaccination in multi-country regression. Having a regular provider was associated with a higher probability of HPV vaccination for children. Health system engagement and health security showed stronger associations with Flu than COVID-19 vaccination and with vaccine uptake compared to vaccine confidence, although these associations varied across countries. Trust in scientists and trusting the national public health agency were also strongly correlated with several vaccine outcomes.</div></div><div><h3>Interpretation</h3><div>Our findings highlight the links between health system engagement, health security, and vaccination rates. Health system engagement may be particularly important to mitigate barriers to vaccination related to ‘complacency’ and ‘convenience’.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127134"},"PeriodicalIF":4.5,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meeting report: Expert consultation on late arresting replication competent (LARC) malaria sporozoite vaccine research & development","authors":"Annie X. Mo,&nbsp;Glen McGugan,&nbsp;John T. Pesce","doi":"10.1016/j.vaccine.2025.127009","DOIUrl":"10.1016/j.vaccine.2025.127009","url":null,"abstract":"<div><div>In June 2024, the National Institute of Allergy and Infectious Diseases (NIAID) convened an expert consultation to guide strategic priorities for the research and development of next-generation whole <em>Plasmodium falciparum</em> sporozoite vaccine candidates. The focus was on genetically attenuated, late (liver stage) arresting replication competent (LARC) sporozoite vaccines. The meeting reviewed the World Health Organization (WHO) Preferred Product Characteristics (PPCs) for future malaria vaccines and drew lessons from previous malaria vaccine R&amp;D and implementation efforts. Key discussions centered on critical features related to the Target Product Profiles (TPP) of LARC vaccines for various specified indications and relevant development strategies. The consultation identified knowledge gaps and suggested priorities and opportunities for future research and product development for LARC malaria sporozoite vaccines.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127009"},"PeriodicalIF":4.5,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the impact of influenza vaccine on preventing stroke hospitalization and death in Chinese elderly hypertensive patients: A retrospective cohort study","authors":"Feng Tong ,&nbsp;Tianshu Zhou ,&nbsp;Ling Tang ,&nbsp;Xiaoqing Wu ,&nbsp;Tianchi Yang ,&nbsp;Lixia Ye","doi":"10.1016/j.vaccine.2025.127004","DOIUrl":"10.1016/j.vaccine.2025.127004","url":null,"abstract":"<div><h3>Background</h3><div>The effect of influenza vaccination on stroke remains controversial, particularly given the paucity of studies conducted in mainland China.</div></div><div><h3>Methods</h3><div>Using a comprehensive database obtained from the Regional Health Information Platform, we conducted a 7-month retrospective cohort analysis of 457,887 elderly individuals residing in an eastern Chinese city. Using multivariate competing risks regression analysis, we derived subdistribution hazard ratios (sHRs) along with the corresponding 95 % confidence intervals (CIs).</div></div><div><h3>Results</h3><div>There was no significant difference in the proportion of hospitalizations for stroke between those who received the influenza vaccine and those who did not (7.50 per 1000 vs. 8.12 per 1000; adjusted sHR: 0.96, 95 % CI: 0.90–1.02). However, a pronounced reduction in stroke-related mortality was observed among vaccinated individuals, with a rate of 0.18 ‰ compared with 0.54 ‰ among the unvaccinated (adjusted sHR: 0.47, 95 % CI: 0.33–0.69).</div></div><div><h3>Conclusion</h3><div>This study highlights the substantial role of influenza vaccination in reducing the risk of stroke-related mortality in elderly hypertensive patients. Therefore, efforts to increase influenza vaccination rates in this population are strongly encouraged.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127004"},"PeriodicalIF":4.5,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143830366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strengthening health security through routine vaccination policy: A comprehensive analysis of childhood vaccination laws across 194 countries","authors":"Ciara M. Weets,&nbsp;Rory Wilson,&nbsp;Heather Swadley,&nbsp;Rebecca Katz","doi":"10.1016/j.vaccine.2025.127121","DOIUrl":"10.1016/j.vaccine.2025.127121","url":null,"abstract":"<div><h3>Background</h3><div>Vaccine preventable diseases (VPD) present a resurgent threat to global health security and jeopardize decades of advancements in public health and economic development. Since 1974, childhood vaccinations are estimated to have prevented 154 million deaths from VPD, yet recent declines in routine vaccination rates highlight the global population's growing vulnerability to these diseases. When paired with appropriate access to healthcare and trusted information, evidence informed enforceable policies have demonstrably improved childhood vaccination rates in countries that have recently implemented more stringent laws on routine vaccination. Here we comprehensively map and describe the current legal environment for childhood vaccination.</div></div><div><h3>Methods</h3><div>We conducted a comprehensive analysis of the childhood vaccination-related policies in 194 countries. Policies were systematically identified, collated, and categorized into a publicly available tool.</div></div><div><h3>Results</h3><div>A total of 106 countries have legally-enforceable policies requiring vaccination for at least one disease. We found that vaccines against diphtheria, measles, and tetanus were the most universally mandated, while vaccines against COVID-19 and Japanese Encephalitis were mandated by the fewest countries. In 91 countries, childhood vaccination requirements are enforced through either legal sanctions, such as monetary fines or incarceration, through exclusion from congregate settings, or through some combination of the two.</div></div><div><h3>Conclusion</h3><div>Analyses of the efficacy of childhood vaccination laws are predicated upon a comprehensive mapping of the current legal landscape related to routine immunization. Public health officials and researchers with an interest in increasing routine childhood vaccination rates in their country must know what characteristics of policy have been effective across various contexts. Our mapping of legally-enforceable childhood vaccination policies is foundational for assessing current vulnerabilities to vaccine-preventable diseases and future policy analyses.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127121"},"PeriodicalIF":4.5,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143830365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opportunities and challenges for the adoption of novel platform technologies to develop veterinary bacterial vaccines","authors":"Gary Entrican ,&nbsp;Helba Bredell ,&nbsp;Johannes Charlier ,&nbsp;Adam F. Cunningham ,&nbsp;Michael A. Jarvis ,&nbsp;Paul R. Wood ,&nbsp;Brendan W. Wren ,&nbsp;Jayne C. Hope","doi":"10.1016/j.vaccine.2025.127117","DOIUrl":"10.1016/j.vaccine.2025.127117","url":null,"abstract":"<div><div>Vaccine platform technologies provide standardised vehicles for the delivery of diverse antigens to elicit specific immune responses. The deployment of these platforms for novel vaccine development is influenced by a wide range of factors that must meet end-user needs for uptake, which includes cost, frequency of delivery and dependency on cold-chain storage. These factors can be identified by constructing a vaccine target product profile (TPP) that helps to direct the research effort towards the desired goal. The COVID-19 pandemic has exemplified how viral vectored and nucleic acid-based platforms can be rapidly deployed for population disease control. While successful for viral vaccines, the applicability of these platforms for bacteria is less well defined. Bacteria present different challenges to vaccine design from viruses due to their diversity and complexity. Other platform technologies are under development to address these challenges. The more we understand about vaccine platforms, the more adaptable they become, particularly for deployment across species with benefits for One Health. A Workshop was held at the 13th International Veterinary Immunology Symposium (IVIS) in South Africa in November 2023 to discuss the opportunities and challenges in deploying novel platform technologies for vaccine development against bacteria, particularly those that are affordable to low-middle income countries (LMICs). We report here on the outcomes of the presentations and discussions at the Workshop, highlighting the gaps and potential solutions through collaborative global efforts.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127117"},"PeriodicalIF":4.5,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143830364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticipated impact of novel adult-specific pneumococcal conjugate vaccine","authors":"R. Joshi,&nbsp;H.T. Ayele,&nbsp;K.D. Johnson,&nbsp;P. Velentgas,&nbsp;H. Platt,&nbsp;P. Saddier","doi":"10.1016/j.vaccine.2025.127080","DOIUrl":"10.1016/j.vaccine.2025.127080","url":null,"abstract":"<div><h3>Background</h3><div>The incidence of IPD in adults, while largely decreased from indirect effect of pediatric PCVs, remains high.</div></div><div><h3>Objective</h3><div>To describe differences in the expected serotype coverage and incidence of IPD by V116, a novel adult-specific PCV, and other licensed PCVs used in adults.</div></div><div><h3>Methods</h3><div>We used national IPD surveillance serotype distribution data from 7 countries (US, Canada, UK, Germany, France, Spain, and Australia). We calculated serotype coverage offered by V116 and PCV20 in adults 65+ (or 60+) years old in 2022 (2019 for UK, France). For all countries except Germany, we reported incidence/notification rates of IPD due to serotypes in V116 versus other PCVs in 2019. As an example, we estimated annual numbers of US cases potentially prevented, assuming 100 % vaccine efficacy and uptake for both vaccines.</div></div><div><h3>Results</h3><div>From 7 countries, coverage conferred by V116 in adults 65+ in 2019–2022 ranged from 66 %–88 % of IPD cases while PCV20 coverage ranged from 50 %–66 %. The incidence of IPD among adults 65+ caused by serotypes included in V116 is higher in all six countries compared to other PCVs in 2019. In US, the annual incidence of IPD (per 100,000) among 65+ was 24; the incidence caused by serotypes in V116 was 20 cases compared to 12 from PCV20 serotypes. Of the estimated total 12,800 annual IPD cases in 2019 in the US, V116 could potentially prevent ∼8200 cases compared to ∼5000 by PCV20.</div></div><div><h3>Conclusions</h3><div>Based on IPD surveillance data from key countries, serotype coverage by V116 was ∼16–33 % higher than that by PCV20 among adults 65+ years in 2022 (data for UK, France from 2019). V116 includes serotypes responsible for the majority of IPD and is expected to prevent more IPD cases than PCV20 among 65+.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 127080"},"PeriodicalIF":4.5,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Antibody persistence in Chinese toddlers at 1 year and 2 years after two different 4-dose schedules of a novel 13-valent pneumococcal conjugate vaccine (PCV13-TT)” [Vaccine 49 (7) (2025) 126815]","authors":"Qiang Ye ,&nbsp;Hong Li ,&nbsp;Zhiqiang Xie ,&nbsp;Xuefen Gao ,&nbsp;Lin Yuan ,&nbsp;Jingjing Chen ,&nbsp;Huilan Fan ,&nbsp;Xuemei Yan ,&nbsp;Siwen Tao ,&nbsp;Yemei Yang ,&nbsp;Junyan Yue ,&nbsp;Jing Shi ,&nbsp;Jianxiang Lin ,&nbsp;Zhiwei Jiang ,&nbsp;Ruoyu Hu ,&nbsp;Lei Shi ,&nbsp;Zhen Huang","doi":"10.1016/j.vaccine.2025.127125","DOIUrl":"10.1016/j.vaccine.2025.127125","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127125"},"PeriodicalIF":4.5,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hybrid, vaccine-induced and natural immunity against SARS-CoV-2 in traditional food markets in Bolivia (2020−2022): A cross-sectional analysis of a serological survey","authors":"Christine Leyns ,&nbsp;Elliot McClenaghan ,&nbsp;Patricia Rodriguez ,&nbsp;Patrick Nguipdop-Djomo ,&nbsp;Carla Ascarrunz ,&nbsp;Daniel Eid Rodriguez ,&nbsp;Punam Mangtani ,&nbsp;Javier Guitian","doi":"10.1016/j.vaccine.2025.127104","DOIUrl":"10.1016/j.vaccine.2025.127104","url":null,"abstract":"<div><h3>Background</h3><div>In low-and middle-income countries, market vendors played a crucial role in food security during the coronavirus pandemic. High numbers of contacts, combined with social, political and health system upheaval in Bolivia, meant they were highly exposed to SARS-CoV-2 infections.</div></div><div><h3>Methods</h3><div>Demographic, clinical and serological data were collected at survey rounds between 2020 and 2022 from a cohort of market vendors in two purposively selected markets where the community and researchers co-promoted health and safety. We used these longitudinal data to examine SARS-CoV-2 anti-spike antibody levels between those vaccinated with and without previous infection and those unvaccinated. The association between antibody levels, and vaccine status, socio-demographic and health information was assessed using linear regression.</div></div><div><h3>Findings</h3><div>A total of 213 market vendors had repeated serological sampling in July, and November 2021, and again in May 2022. In November 2020, 105 (49.3 %) of this cohort had participated in a pre-vaccination municipal serological survey. Seroprevalence then was 45·7 % (95 %CI 36·3–55·4). By November 2021, 67·8 % of the full cohort had one vaccination and seroprevalence was 83·6 %. We showed IgG levels in those seropositive were higher in participants with evidence of vaccination and prior infection compared to those unvaccinated. By May 2022, the majority of participants developed antibodies against SARS-CoV-2, and these differences were attenuated.</div></div><div><h3>Interpretation</h3><div>A substantial proportion of vendors were susceptible to SARS-CoV-2 in late 2020 when, nationally, excess mortality was high. Our analyses suggested a combination of natural infection and vaccination provided better protective antibody levels than natural infection alone at the peak of the pandemic. Future pandemic planning requires timely targeted serological surveys to understand pandemic dynamics and support prompt interventions. In addition, communication with organized communities can inform effectiveness of pandemic mitigation strategies including improved vaccination uptake. Timely quantitative IgG level monitoring can also inform waning immunity.</div></div><div><h3>Funding</h3><div>This study was supported by the Medical Research Council and a National Institutes for Health and Care Research (NIHR) Global Effort on COVID-19 (GECO) Health Research award 2020 [MR/V028561/1].</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127104"},"PeriodicalIF":4.5,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}